Soleil Boughton Sells 54,153 Shares of Hims & Hers Health, Inc. (NYSE:HIMS) Stock

Hims & Hers Health, Inc. (NYSE:HIMS) insider Soleil Boughton sold 54,153 shares of the stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $29.90, for a total value of $1,619,174.70. Following the sale, the insider now directly owns 165,650 shares of the company’s stock, valued at approximately $4,952,935. This trade represents a 24.64 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.

Soleil Boughton also recently made the following trade(s):

• On Monday, January 6th, Soleil Boughton sold 268,932 shares of Hims & Hers Health stock. The shares were sold at an average price of $27.75, for a total value of $7,462,863.00.
• On Tuesday, November 26th, Soleil Boughton sold 2,343 shares of Hims & Hers Health stock. The shares were sold at an average price of $29.90, for a total value of $70,055.70.
• On Tuesday, October 29th, Soleil Boughton sold 2,339 shares of Hims & Hers Health stock. The shares were sold at an average price of $23.16, for a total value of $54,171.24.

Hims & Hers Health Stock Performance

Shares of NYSE HIMS opened at $30.89 on Friday. Hims & Hers Health, Inc. has a fifty-two week low of $8.51 and a fifty-two week high of $35.02. The company has a 50 day simple moving average of $28.22 and a two-hundred day simple moving average of $22.17. The company has a market capitalization of $6.75 billion, a price-to-earnings ratio of 70.20 and a beta of 1.31.

Hims & Hers Health (NYSE:HIMS) last announced its earnings results on Monday, November 4th. The company reported $0.32 earnings per share for the quarter, beating analysts’ consensus estimates of $0.06 by $0.26. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The business had revenue of $401.56 million during the quarter, compared to the consensus estimate of $382.20 million. During the same quarter last year, the firm earned ($0.04) earnings per share. The business’s revenue for the quarter was up 77.1% on a year-over-year basis. On average, analysts forecast that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Analyst Ratings Changes

HIMS has been the subject of a number of analyst reports. Citigroup lowered Hims & Hers Health from a “neutral” rating to a “sell” rating and increased their price objective for the company from $24.00 to $25.00 in a research note on Friday, January 10th. Deutsche Bank Aktiengesellschaft lifted their price target on shares of Hims & Hers Health from $23.00 to $27.00 and gave the company a “hold” rating in a report on Wednesday, November 6th. BTIG Research began coverage on shares of Hims & Hers Health in a report on Tuesday, January 7th. They issued a “buy” rating and a $35.00 price target on the stock. Piper Sandler increased their price target on shares of Hims & Hers Health from $21.00 to $24.00 and gave the stock a “neutral” rating in a research note on Monday, January 6th. Finally, Morgan Stanley began coverage on shares of Hims & Hers Health in a research note on Tuesday, December 17th. They issued an “overweight” rating and a $42.00 price target for the company. Two analysts have rated the stock with a sell rating, seven have issued a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $25.13.

Institutional Investors Weigh In On Hims & Hers Health

Several institutional investors and hedge funds have recently made changes to their positions in HIMS. Raleigh Capital Management Inc. increased its position in shares of Hims & Hers Health by 1,100.0% during the fourth quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company’s stock valued at $29,000 after acquiring an additional 1,100 shares in the last quarter. GAMMA Investing LLC increased its position in shares of Hims & Hers Health by 2,173.7% during the fourth quarter. GAMMA Investing LLC now owns 2,251 shares of the company’s stock valued at $54,000 after acquiring an additional 2,152 shares in the last quarter. Quest Partners LLC increased its position in shares of Hims & Hers Health by 22.6% during the third quarter. Quest Partners LLC now owns 4,373 shares of the company’s stock valued at $81,000 after acquiring an additional 807 shares in the last quarter. CWM LLC increased its position in shares of Hims & Hers Health by 21.4% during the third quarter. CWM LLC now owns 5,982 shares of the company’s stock valued at $110,000 after acquiring an additional 1,054 shares in the last quarter. Finally, Nisa Investment Advisors LLC increased its position in shares of Hims & Hers Health by 115.3% during the fourth quarter. Nisa Investment Advisors LLC now owns 4,560 shares of the company’s stock valued at $110,000 after acquiring an additional 2,442 shares in the last quarter. Institutional investors own 63.52% of the company’s stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.